The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus
- 1 January 2016
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 125, 71-78
Abstract
No abstract availableKeywords
Funding Information
- Centers for Disease Control and Prevention
This publication has 15 references indexed in Scilit:
- Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever virusesAntiviral Research, 2015
- Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United StatesAnnals of Internal Medicine, 2015
- Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus DiseaseClinical Infectious Diseases, 2015
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse modelAntiviral Research, 2014
- Ebolavirus Requires Acid Sphingomyelinase Activity and Plasma Membrane Sphingomyelin for InfectionJournal of Virology, 2012
- Development of CMX001 for the Treatment of Poxvirus InfectionsViruses, 2010
- Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside PhosphonateViruses, 2010
- Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir DiphosphateAntimicrobial Agents and Chemotherapy, 2005
- Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screeningVirology, 2005